Robert S. Kerbel, PhD, reviews the latest preclinical and clinical findings on the use of angiogenesis inhibitors to treat cancer, including mechanisms of resistance, the relevance of tumor flare-up after discontinuation of antiangiogenic therapy, and potential markers to predict clinical benefit.
Learning Objectives
Upon completion of this activity, participants should be able to:
- Describe the mechanisms of targeting angiogenesis
- Explain the mechanisms of resistance to antiangiogenic drugs
- Describe the phenomenon of rebound or tumor flare that may result from the discontinuation of antiangiogenic therapy
- Evaluate data supporting the use of angiogenesis inhibitors in the neoadjuvant, adjuvant, and metastatic settings
- Assess the potential clinical role of biomarkers of response to antiangiogenic therapy
